Concurrent treatment with TGF-β-blocking antibodies and anti-PD-L1 antibodies reduces TGF-β signaling in stromal cells, promotes T cell infiltration into the tumor core, and elicits robust anti-tumor immunity and tumor regression 162. The gene discussed is CD274; the disease is neoplasm.